|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia 显示文摘 | Pardanani A Lasho TL Laborde RR | 2013 | Leukemia2013，27，9： | 1 |
| 2 | Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis 显示文摘 | Pardanani A Laborde RR Lasho TL | 2013 | Leukemia2013，27，6： | 1 |
| 3 | CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia显示文摘 | Pardanani A Lasho TL Laborde RR | 2013 | Leukemia2013，27，9： | 1 |
| 4 | CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia 显示文摘 | Pardanani A Lasho TL Laborde RR | 2013 | Leukemia2013，27，9： | 1 |
| 5 | Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis 显示文摘 | Pardanani A Laborde RR Lasho TL | 2013 | Leukemia2013，27，6： | 1 |
| 6 | Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carciuoma显示文摘 | Moore EJ Olsen SM Laborde RR | | 0，，03： | 1 |
| 7 | Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis 显示文摘 | Pardanani A Laborde RR Lasho TL | 2013 | Leukemia2013，27，6： | 1 |
| 8 | CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia显示文摘 | Pardanani A Lasho TL Laborde RR | 2013 | Leukemia2013，27，9： | 1 |
| 9 | Safety and ef- ficacy of CYT387 ,a JAK1 and JAN2 inhibitor,in myelofi- brosis显示文摘 | Pardanani A Laborde RR Lasho TL | 2013 | Leukemia2013，27，6： | 1 |
| 10 | SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia:independent prognostic impact in CMML显示文摘 | Laborde RR Patnaik MM Lasho TL | 2013 | Leukemia2013，27，： | 1 |
| 11 | Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis 显示文摘 | Pardanani A Laborde RR Lasho TL | 2013 | Leukemia2013，27，6： | 1 |
| 12 | SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonoeytie leukemia: independent prognostic impact in CMML显示文摘 | Laborde RR Patnaik MM Lasho TL | 2013 | Leukemia2013，27，10： | 1 |
| 13 | Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis显示文摘 | Pardanani A Laborde RR Lasho TL | 2013 | Leukemia2013，27，： | 1 |
| 14 | CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia 显示文摘 | Pardanani A Lasho TL Laborde RR | 2013 | Leukemia2013，27，9： | 1 |
| 15 | CSF3R T6181 is a highly prevalent andspecific mutation in chronic neutrophilicleukem ia显示文摘 | Pardanani A Lasho TL Laborde RR etal | 2013 | Leukem ia2013，27，9： | 1 |
| 16 | Linking expression ofFOXM1,CEP55 and HELLS to tumorigenesis in oropharyngealsquamous cell carcinoma 显示文摘 | Janus JR Laborde RR Greenberg AJ | 2011 | Laryngoscope2011，121，12： | 1 |
| 17 | Imetelstat,a telomerase inhibitor,induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis显示文摘 | Begna K Laborde RR Patnaik MM | 2013 | Blood2013，122，： | 1 |
| 18 | Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis显示文摘 | Pardanani A Laborde RR Lasho TL | 2013 | Leukemia2013，27，6： | 1 |
| 19 | CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia显示文摘 | Pardanani A Lasho TL Laborde RR | 2013 | Leukemia2013，27，9： | 1 |
| 20 | Linking expres- sion of FOXM1 ,CEP55 and HELLS to tumorigenesis in oro- pharyngeal squamous cell carcinoma 显示文摘 | Janus JR Laborde RR Greenberg AJ | 2011 | Laryngoscope2011，121，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员